Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J3245 Injection., tildrakizumab, 1 milligrams

J Codes (Drugs)

Also known as: tildrakizumab, Ilumya, interleukin-23 inhibitor

Tildrakizumab 1 milligram injection is a monoclonal antibody targeting interleukin-23 used for moderate to severe plaque psoriasis and psoriatic arthritis treatment.

In Plain Language

psoriasis treatment injection; skin condition medication

Clinical Context

Indicated for moderate to severe plaque psoriasis and psoriatic arthritis. Biologic therapy targeting interleukin-23 pathway. Administered subcutaneously every 12 weeks after initial loading doses.

RVU Information

CPT J3245 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

DermatologyRheumatologyInternal Medicine

Frequently Asked Questions

What is CPT code J3245?

CPT J3245 (Injection., tildrakizumab, 1 milligrams) is a J Codes (Drugs) code. Tildrakizumab 1 milligram injection is a monoclonal antibody targeting interleukin-23 used for moderate to severe plaque psoriasis and psoriatic arthritis treatment.

How is J3245 administered?

CPT J3245 is administered by a healthcare provider, typically via injection or infusion. Indicated for moderate to severe plaque psoriasis and psoriatic arthritis. Biologic therapy targeting interleukin-23 pathway. Administered subcutaneously every 12 weeks after initial loading doses. It is used by Dermatology, Rheumatology, Internal Medicine.

When is CPT J3245 used?

Indicated for moderate to severe plaque psoriasis and psoriatic arthritis. Biologic therapy targeting interleukin-23 pathway. Administered subcutaneously every 12 weeks after initial loading doses.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.